The FCF Biotech Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US-Biotech sector.
As of the end of November 2021, we identify the following current VC trends in the US-Biotech sector:
- In 2021, overall Biotech funding in the USA has reached USD 30,945m so far
- Top 5 deals exceed USD 400m each, largest transaction amounted to USD 735m in Treeline Biosciences, Inc.
- Logos Capital (USA) leads the Top 5 Investors (by deal volume), followed by ARCH Venture Partners (USA) and OrbiMed (USA)
- Oncology dominates as the top indication
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
FCF Biotech Venture Capital Monitor – USA 11/2021 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 11/2021”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
In-Licensing by Chinese Biotech Companies on the rise
An increasing number of drugs of European origin have been in-licensed to Chinese biotechnology companies. Over the last five years, a steady increase in the number of yearly in-licensed assets from Europe can be observed.
FCF Life Sciences Venture Capital Monitor – Europe 11/2021 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 11/2021”. The Monitor is a monthly published overview of venture capital trends in the European Life
VC market for cannabis gains momentum
Investment into US and European cannabis companies have been continuously increasing over the past years. Whereas 72 venture capital transactions were conducted in 2016, the number of transactions in 2021 (YTD) have increased by almost
FCF Biotech Venture Capital Monitor – USA 10/2021 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 10/2021”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
